RETRACTED ARTICLE: Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways-Reference-Cited by-同舟云学术

RETRACTED ARTICLE: Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways

Published:2023-11-02 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Üremis Nuray,Türköz Yusuf,Üremiş Muhammed Mehdi,Çiğremiş Yılmaz,Şalva Emine

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00210-023-02811-z.pdf

Reference59 articles.

1. Adnane L, Trail PA, Taylor I, Wilhelm SM (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597–612

2. Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM (2019) Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicina (Kaunas) 55

3. Altinoz E, Oner Z, Elbe H, Uremis N, Uremis M (2022) Linalool exhibits therapeutic and protective effects in a rat model of doxorubicin-induced kidney injury by modulating oxidative stress. Drug Chem Toxicol 45:2024–2030

4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

5. Cao S, Zhu S, Yin W, Xu H, Wu J, Wang Q (2020) Relevance of EGFR between serum VEGF and MMP-9 in primary hepatocellular carcinoma patients with transarterial chemoembolization. Onco Targets Ther 13:9407–9417